The use of probiotics in reducing inflammation caused by metabolic syndrome: an integrative review
Keywords:Inflammation mediators; Metabolic Syndrome; Probiotics.
The Metabolic Syndrome (MS) represents a condition of pro-thrombotic and pro-inflammatory state characterized by increased inflammatory activity of cytokines. Dysbiosis processes have been associated with obesity, present in MS, so the use of probiotics has been considered as an alternative to traditional approaches to weight loss and a low-calorie diet, provided they are consumed in adequate amounts. This is an integrative literature review, whose guiding question “Does the use of probiotics reduce the inflammation generated by the metabolic syndrome?” induced the research carried out in the databases: SCIELO, VHL, PUBMED and Science Direct. The descriptors “inflammation”, “probiotic”, “metabolic syndrome” and “insulin resistance” were used. The articles were analyzed using the PRISMA model, and 8 articles were included in the final sample for review. All included studies were published in the year 2017 to 2022 in English. The probiotic effect on body weight is dependent on a number of factors, such as the species and strains of microorganisms and the time of administration of the probiotic. Some of them have been widely used in patients with MS to reduce the inflammatory state of the body, acting mainly in reducing body weight, BMI, waist and hip circumferences, systolic and diastolic blood pressure. In addition, there was a reduction in pro-inflammatory markers such as interleukin 5 and C-reactive protein with the use of probiotics. These findings justify the need for multicentric research, with a heterogeneous population to be analyzed in order to accurately determine the therapeutic effects of probiotics in reducing inflammatory markers and cardiometabolic risk factors in patients with MS.
Andriani, N., Quessada, L., Quessada, L., Camporeze, B., Soffiatti, F., & Guastalli, G. (2018). Inter-Relação Entre Microbiota Intestinal E Síndrome Metabólica: Futuro Tratamento Promissor. International Journal of Nutrology. https://doi.org/10.1055/s-0038-1674792
Araújo, L. M. B., Britto, M. M. dos S., & Porto da Cruz, T. R. (2000). Tratamento do diabetes mellitus do tipo 2: novas opções. Arquivos Brasileiros de Endocrinologia & Metabologia, 44(6), 509–518. https://doi.org/10.1590/s0004-27302000000600011
Barbalho, S. M., Bechara, M. D., Quesada, K., Gabaldi, M. R., Goulart, R. de A., Tofano, R. J., & Gasparini, R. G. (2015). Síndrome metabólica, aterosclerose e inflamação: tríade indissociável? Jornal Vascular Brasileiro, 14(4), 319–327. https://doi.org/10.1590/1677-5449.04315
Brancher, J. S. (2014). Uso de probióticos no tratamento da obesidade: uma revisão sistemática [Trabalho de Conclusão de Curso (Bacharel em Nutrição)].
Cheng, A. Y. Y. (2005). Oral antihyperglycemic therapy for type 2 diabetes mellitus. Canadian Medical Association Journal, 172(2), 213–226. https://doi.org/10.1503/cmaj.1031414
Cicero, A. F. G., Fogacci, F., Bove, M., Giovannini, M., & Borghi, C. (2021). Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. European Journal of Nutrition, 60(2), 655–663. https://doi.org/10.1007/s00394-020-02271-8
Depommier, C., Everard, A., Druart, C., Maiter, D., Thissen, J.-P., Loumaye, A., Hermans, M. P., Delzenne, N. M., de Vos, W. M., & Cani, P. D. (2021). Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome. Gut Microbes, 13(1). https://doi.org/10.1080/19490976.2021.1994270
Grandl, G., & Wolfrum, C. (2018). Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Seminars in Immunopathology, 40(2), 215–224. https://doi.org/10.1007/s00281-017-0666-5
Kazemi, A., Soltani, S., Ghorabi, S., Keshtkar, A., Daneshzad, E., Nasri, F., & Mazloomi, S. M. (2019). Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. Clinical Nutrition, 39(3). https://doi.org/10.1016/j.clnu.2019.04.004
Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J.-M., Rizkalla, S., Schrezenmeir, J., & Clément, K. (2019). Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open, 9(3), e017995. https://doi.org/10.1136/bmjopen-2017-017995
McCracken, E., Monaghan, M., & Sreenivasan, S. (2018). Pathophysiology of the metabolic syndrome. Clinics in Dermatology, 36(1), 14–20. https://doi.org/10.1016/j.clindermatol.2017.09.004
Nunes, M. L., & Garrido, M. P. (2019). A obesidade e a ação dos prebióticos, probióticos e simbióticos na microbiota intestinal. Nutrição Brasil, 17(3), 189–196. https://doi.org/10.33233/nb.v17i3.907
Penalva, D. Q. F. (2008). Síndrome metabólica: diagnóstico e tratamento. Revista de Medicina, 87(4), 245. https://doi.org/10.11606/issn.1679-9836.v87i4p245-250
Rabiei, S., Hedayati, M., Rashidkhani, B., Saadat, N., & Shakerhossini, R. (2018). The Effects of Synbiotic Supplementation on Body Mass Index, Metabolic and Inflammatory Biomarkers, and Appetite in Patients with Metabolic Syndrome: A Triple-Blind Randomized Controlled Trial. Journal of Dietary Supplements, 16(3), 294–306. https://doi.org/10.1080/19390211.2018.1455788
Rezazadeh, L., Alipour, B., Jafarabadi, M. A., & Gargari, B. P. (2020). Evaluation of the effects of probiotic yoghurt on inflammation and cardiometabolic risk factors in subjects with metabolic syndrome: A randomised controlled trial. International Dairy Journal, 101, 104577. https://doi.org/10.1016/j.idairyj.2019.104577
Rochlani, Y., Pothineni, N. V., Kovelamudi, S., & Mehta, J. L. (2017). Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic Advances in Cardiovascular Disease, 11(8), 215–225. https://doi.org/10.1177/1753944717711379
Samson, S. L., & Garber, A. J. (2014). Metabolic syndrome. Endocrinology and Metabolism Clinics of North America, 43(1), 1–23. https://doi.org/10.1016/j.ecl.2013.09.009
Sato, J., Kanazawa, A., Azuma, K., Ikeda, F., Goto, H., Komiya, K., Kanno, R., Tamura, Y., Asahara, T., Takahashi, T., Nomoto, K., Yamashiro, Y., & Watada, H. (2017). Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-12535-9
Silva-Júnior, A. do C., Cruz, D. P., Vitório De Souza Junior, E., Souza Rosa, R., Missias Moreira, R., & Santana Cardoso Santos, I. (2020). [Repercussions of the prevalence of metabolic syndrome on adults and elderly people in the context of primary health care]. Revista de Salud Publica (Bogota, Colombia), 20(6), 735–740. https://doi.org/10.15446/rsap.V20n6.65564
Sociedade Brasileira de Cardiologia. (2005). I Diretriz Brasileira de diagnóstico e tratamento da síndrome metabólica. https://www.scielo.br/j/abc/a/qWzJH647dkF7H5dML8x8Nym/?format=pdf&lang=pt
Souza, M. T. de, Silva, M. D. da, & Carvalho, R. de. (2010). Integrative review: what is it? How to do it? Einstein (São Paulo), 8(1), 102–106. https://doi.org/10.1590/s1679-45082010rw1134
Tenorio-Jiménez, C., Martínez-Ramírez, M. J., Del Castillo-Codes, I., Arraiza-Irigoyen, C., Tercero-Lozano, M., Camacho, J., Chueca, N., García, F., Olza, J., Plaza-Díaz, J., Fontana, L., Olivares, M., Gil, Á., & Gómez-Llorente, C. (2019). Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. Nutrients, 11(8), E1761. https://doi.org/10.3390/nu11081761
How to Cite
Copyright (c) 2022 Michel Patrik de Sousa Arruda; Mateus Bueno de Pinho Oliveira; Irineu Rasera Jr
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.